Financials
Financial year 2025
Laura Peter CardioInterv from Messancy, company number BE1022217375, closed financial year 2025 with a result of € -2,278 after tax. For that financial year Laura Peter CardioInterv recorded a gross margin of € -2,228 and equity of € 1,722. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 30, 2026.
€ 1,722
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2,278
Profit after tax over the fiscal year.
€ 4,121
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2,278.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
What happened to Laura Peter CardioInterv?
What happened at Laura Peter CardioInterv in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 2,278. Source: NBB ↗
- New establishment in Messancy. KBO
- Laura PETER became a director. NBB
- Start of the company according to the CBE. KBO
Management
Behind Laura Peter CardioInterv is Laura PETER.
Directors
According to the 2025 annual accounts
Laura PETER
Director
since 2025
Establishments
Establishment units
Physical locations of this company
Rue des Rochers,Hondelange 87
6780 Messancy
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1022.217.375
- VAT number
- BE 1022.217.375
- Registered office
- Rue des Rochers,Hondelange 87, 6780 Messancy
- Names & denominations
- Laura Peter CardioInterv
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 April 2025
- Peppol
- Active · Active since 7 Oct 2026
- Contact
- [email protected]